Extracellular LGALS3BP : a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma
Molecular Oncology · 2023
DOI: 10.1002/1878-0261.13453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Beatrice Dufrusine und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Innovative Technologies in Medicine & Dentistry, University "G. D'Annunzio" of Chieti-Pescara, Italy. Hauptthemen laut MEDLINE: Glioblastoma, Immunoconjugates, Extracellular Vesicles, Brain Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is a lethal disease characterized by an overall survival of about 1 year, making it one of the most aggressive tumours, with very limited therapeutic possibilities. Specific biomarkers for early diagnosis as well as innovative therapeutic strategies are urgently needed to improve the management of this deadly disease. In this work, we demonstrated that vesicular galectin‐3‐binding protein (LGALS3BP), a glycosylated protein overexpressed in a variety of human malignancies, is a potential GBM disease marker and can be efficiently targeted by a specific antibody–drug conjugate (ADC). Immunohistochemical analysis on patient tissues showed that LGALS3BP is highly expressed in GBM and, compared with healthy donors, the amount of vesicular but not total circulating protein is increased. Moreover, analysis of plasma‐derived extracellular vesicles from mice harbouring human GBM revealed that LGALS3BP can be used for liquid biopsy as a marker of disease. Finally, an ADC targeting LGALS3BP, named 1959‐sss/DM4, specifically accumulates in tumour tissue, producing a potent and dose‐dependent antitumor activity. In conclusion, our work provides evidence that vesicular LGALS3BP is a potential novel GBM diagnostic biomarker and therapeutic target deserving further preclinical and clinical validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Innovative Technologies in Medicine & Dentistry, University "G. D'Annunzio" of Chieti-Pescara, Italy.
- Center for Advanced Studies and Technology (CAST), Chieti, Italy.
- Department of Bioscience and Technology for Food Agriculture and Environment, University of Teramo, Italy.
- Department of Life, Health and Environmental Sciences, University of L'Aquila, Coppito, Italy.
- Department of Medicine and Aging Sciences, University "G. D'Annunzio" of Chieti-Pescara, Chieti, Italy.
- MediaPharma s.r.l., Chieti, Italy.
ORCID-Profile: Beatrice Dufrusine, Gianluca Trevisi, Gianluca Sala
Förderung
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Dufrusine, B., Capone, E., Ponziani, S., Lattanzio, R., Lanuti, P., Giansanti, F., De Laurenzi, V., Iacobelli, S., Ippoliti, R., Mangiola, A., Trevisi, G., & Sala, G. (2023). Extracellular LGALS3BP : a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.13453
Vancouver
Dufrusine B, Capone E, Ponziani S, Lattanzio R, Lanuti P, Giansanti F, et al. Extracellular LGALS3BP : a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma. Molecular Oncology. 2023. doi:10.1002/1878-0261.13453
BibTeX
@article{Dufrusine2023,
author = {Dufrusine, Beatrice and Capone, Emily and Ponziani, Sara and Lattanzio, Rossano and Lanuti, Paola and Giansanti, Francesco and De Laurenzi, Vincenzo and Iacobelli, Stefano and Ippoliti, Rodolfo and Mangiola, Annunziato and Trevisi, Gianluca and Sala, Gianluca},
title = {Extracellular LGALS3BP : a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma},
journal = {Molecular Oncology},
year = {2023},
doi = {10.1002/1878-0261.13453}
}
EUVIMED